CEACAM4: A Potential Drug Target and Biomarker for Non-Specific Cross-Reactive Antigen W236

Target Name: CEACAM4

NCBI ID: G1089

CEACAM4

CEACAM4: A Potential Drug Target and Biomarker for Non-Specific Cross-Reactive Antigen W236

Abstract:

Non-specific cross-reacting antigen (NSCA) W236 is a protein that has been found in various tissues and fluids, including blood, urine, and tissue biopsies. It has been demonstrated to play a role in the immune response and has been implicated in a variety of diseases, including autoimmune disorders and cancer. While the exact function of NSCA W236 remains unclear, it is possible that it may serve as a drug target or biomarker. In this article, we will explore the potential role of CEACAM4, a protein that is highly homologous to NSCA W236, as a drug target and biomarker for NSCA W236.

Introduction:

Non-specific cross-reacting antigen (NSCA) W236 is a protein that has been found in various tissues and fluids, including blood, urine, and tissue biopsies. It is characterized by its ability to react with a wide range of antigens, including self -antigens and foreign agens. This property has led to its involvement in a variety of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. While the exact function of NSCA W236 remains unclear, it is possible that it may play a role in the immune response by regulating the activity of immune cells and promoting the rejection of foreign antigens.

Recent studies have identified CEACAM4, a protein that is highly homologous to NSCA W236, as a potential drug target and biomarker for NSCA W236. CEACAM4 is a member of the Camelot family, which includes several proteins that are involved in the development and maintenance of the immune system. Homologous proteins, such as CEACAM4, have been identified in a variety of organisms, including humans, and are thought to play a similar role in the immune response.

The Potential Role of CEACAM4 as a Drug Target:

CEACAM4 has been shown to interact with several protein molecules, including the T-cell receptor (TCR) and the B-cell receptor (BCR). These interactions suggest that CEACAM4 may play a role in the regulation of immune cell function and the development of autoimmune disorders. Additionally, CEACAM4 has been shown to interact with the protein PD-L1, which is a known regulator of immune cell function. This interaction suggests that CEACAM4 may play a role in the regulation of immune cell responses and the development of cancer.

The Potential Role of CEACAM4 as a Biomarker:

In addition to its potential role as a drug target, CEACAM4 may also serve as a biomarker for NSCA W236. Non-specific cross-reacting antigen (NSCA) W236 has been shown to be involved in the development and progression of a variety of diseases, including autoimmune disorders and cancer. It is possible that CEACAM4 may play a role in the regulation of NSCA W236 and its involvement in these diseases.

Conclusion:

In conclusion, CEACAM4 is a protein that is highly homologous to NSCA W236 and has been shown to interact with several protein molecules that are involved in the immune response and the development of autoimmune disorders, cancer, and neurodegenerative diseases. These interactions suggest that CEACAM4 may play a role in the regulation of immune cell responses and the development of these diseases. Additionally, CEACAM4 has been shown to interact with the protein PD-L1, which is a known regulator of immune cell function. These interactions also suggest that CEACAM4 may play a role in the regulation of immune cell responses and the development of cancer. Further research is needed to fully understand the role of CEACAM4 in the immune response and the development of disease.

Protein Name: CEA Cell Adhesion Molecule 4

Functions: Granulocyte orphan receptor that acts as an trigger efficient phagocytosis of attached particles

The "CEACAM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEACAM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets